Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5446 to 5460 of 7685 results

  1. NICE recommends further research to demonstrate the utility of the Sonoclot system in detecting, managing and monitoring haemostasis in cardiac surgery.

    Recommendation ID DG13/1 Question NICE recommends further research to demonstrate the utility of the Sonoclot system in detecting, managing

    Research recommendation
    Published
    9 June 2015

  2. NICE recommends further research to establish optimal target dose ranges for 5-FU plasma levels in people with head and neck cancer, stomach cancer and pancreatic cancer.

    Recommendation ID DG16/3 Question NICE recommends further research to establish optimal target dose ranges for 5-FU plasma levels in people

    Research recommendation
    Published
    9 June 2015

  3. NICE recommends further research to investigate the clinical effectiveness of the integrated sensor-augmented insulin pump therapy systems in younger children and pregnant women. No data are currently available for these subgroups and their inclusion in future studies is encouraged.

    Recommendation ID DG21/2 Question NICE recommends further research to investigate the clinical effectiveness of the integrated sensor-augmented

    Research recommendation
    Published
    11 April 2016

  4. NICE recommends further research to quantify the impact of hypoglycaemia on quality of life for people with type 1 diabetes and their carers.Future research should include adults and children and should capture the impact of persistent anxiety associated with the fear of catastrophic events related to severe hypoglycaemic events.

    Recommendation ID DG21/1 Question NICE recommends further research to quantify the impact of hypoglycaemia on quality of life for people

    Research recommendation
    Published
    11 April 2016

  5. NICE recommends further research to understand the characteristics of patients at high risk of haemostatic instability in whom viscoelastometric testing may be most cost effective.

    Recommendation ID DG13/5 Question NICE recommends further research to understand the characteristics of patients at high risk of haemostatic

    Research recommendation
    Published
    9 June 2015

  6. NICE recommends further research to validate the accuracy and precision of the My5-FU assay for the quantitative determination of 5-fluorouracil (5-FU) at the lower end of its measuring range with analytical reference standard methods, including high-performance liquid chromatography and liquid chromatography-mass spectrometry.

    Recommendation ID DG16/1 Question NICE recommends further research to validate the accuracy and precision of the My5-FU assay for the quantitative

    Research recommendation
    Published
    9 June 2015

  7. NICE recommends research generating and analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim.

    Recommendation ID TA293/2 Question NICE recommends research generating and analysing observational data including, but not limited to,

    Research recommendation
    Published
    9 June 2015

  8. [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.

    Recommendation ID TA161/2 Question [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the

    Research recommendation
    Published
    9 June 2015

  9. NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system in detecting sentinel lymph node metastases during breast cancer surgery. It also recommends that data on all patients having whole lymph node analysis by the RD-100i OSNA system should be submitted to this registry. These data should be integrated with data from other registries for breast cancer where appropriate.

    Recommendation ID DG8/1 Question NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system

    Research recommendation
    Published
    9 June 2015

  10. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    Recommendation ID TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts

    Research recommendation
    Published
    9 June 2015

  11. NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation test methods are performed. These studies should include the re-testing of stored non-small-cell lung cancer (NSCLC) tumour samples using different EGFR-TK mutation test methods and should link to patient outcomes.

    Recommendation ID DG9/1 Question NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase

    Research recommendation
    Published
    9 June 2015

  12. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    Recommendation ID TA274/1 Question NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab

    Research recommendation
    Published
    9 June 2015

  13. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Recommendation ID TA254/1 Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related

    Research recommendation
    Published
    9 June 2015

  14. NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital episode, with a view to informing the cost-effectiveness modelling and reducing uncertainty.

    Recommendation ID DG13/4 Question NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital

    Research recommendation
    Published
    9 June 2015

  15. NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the following arrangements are in place: - coordination of eculizumab use through an expert centre - monitoring systems to record the number of people with a diagnosis of atypical - haemolytic uraemic syndrome and the number who have eculizumab, and the dose and duration of treatment - a national protocol for starting and stopping eculizumab for clinical reasons - a research programme with robust methods to evaluate when stopping treatment or dose adjustment might occur.

    Recommendation ID HST1/1 Question NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the

    Research recommendation
    Published
    9 June 2015